|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...139140141142143144145146147148149...156157» |
- ||| Trial completion, Adherence: Observational Study on Non-steroid Anti-inflammatory Drugs (NSAIDs) Treated Patients With Arthritic Disorder (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=1149, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Observational data: An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=143, Recruiting, Sponsor: Hoffmann-La Roche
- Synavive (prednisolone/dipyridamole) / Sun Pharma
New P2 trial: Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jun 3, 2012
P2, N=18, Terminated, Sponsor: Zalicus
- Apidra (insulin glulisine) / Sanofi
Trial termination: Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents (clinicaltrials.gov) - Jun 3, 2012
P=N/A, N=44, Terminated, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed Recruiting --> Terminated
- Apidra (insulin glulisine) / Sanofi
Enrollment change: Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents (clinicaltrials.gov) - Jun 3, 2012
P=N/A, N=44, Terminated, Sponsor: Rabin Medical Center
Recruiting --> Terminated N=134 --> 44
- | Victoza (liraglutide) / Novo Nordisk
New P4 trial: Liraglutide in Type 1 Diabetes (clinicaltrials.gov) - Jun 3, 2012
P4, N=100, Recruiting, Sponsor: Steno Diabetes Center
- | avdoralimab (IPH5401) / Innate
New P1 trial: First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 3, 2012
P1, N=36, Completed, Sponsor: Novo Nordisk
- ||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s) (clinicaltrials.gov) - Jun 3, 2012
P3, N=461, Completed, Sponsor: Centocor, Inc.
N=134 --> 44 Active, not recruiting --> Completed
- ||| Privigen (human immune globulin intravenous 10%) / CSL Behring
Preclinical, Trial initiation date: A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Jun 2, 2012
P4, N=150, Recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Nov 2011
- | Benlysta (belimumab) / GSK
New P2 trial, IO biomarker: A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy (clinicaltrials.gov) - May 31, 2012
P2, N=18, Recruiting, Sponsor: GlaxoSmithKline
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
New P3 trial: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION) (clinicaltrials.gov) - May 31, 2012
P3, N=121, Completed, Sponsor: Hoffmann-La Roche
- | Plegridy (PEG-interferon ?-1a) / Biogen
New P1 trial: Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers (clinicaltrials.gov) - May 31, 2012
P1, N=30, Completed, Sponsor: Biogen Idec
- |||||||||| blisibimod (A-623) / Anthera Pharma
New P2/3 trial: MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (clinicaltrials.gov) - May 30, 2012
P2/3, N=60, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: ASPECT: Avonex PEN Satisfaction and Patients Experience Clinical Trial (clinicaltrials.gov) - May 30, 2012
P=N/A, N=89, Completed, Sponsor: Biogen Idec
Initiation date: Jul 2011 --> Nov 2011 Active, not recruiting --> Completed
- Promacta (eltrombopag) / Novartis
New P2 trial: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) (clinicaltrials.gov) - May 30, 2012
P2, N=26, Recruiting, Sponsor: Fondazione Progetto Ematologia
- | opicinumab (BIIB033) / Biogen
Trial completion, IO biomarker: Safety Study of BIIB033 in Subjects With Multiple Sclerosis (clinicaltrials.gov) - May 30, 2012
P1, N=47, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Orencia (abatacept) / BMS
P2b data, Enrollment change: Abatacept With Methotrexate- Phase IIB (clinicaltrials.gov) - May 29, 2012
P2b, N=524, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=219 --> 524
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Muscara: Doppler Evaluation in RA Patients After Adalimumab. (clinicaltrials.gov) - May 29, 2012
P4, N=120, Not yet recruiting, Sponsor: Ronald van Vollenhoven, prof.
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial termination: Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis (clinicaltrials.gov) - May 29, 2012
P=N/A, N=1, Terminated, Sponsor: Tufts Medical Center
Suspended --> Terminated; Hyperintensities of unclear etiology on brain MRI. Follow up revealed no progression.
- pioglitazone / Generic mfg.
Trial completion: Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - May 29, 2012
P1, N=15, Completed, Sponsor: Stony Brook University
Follow up revealed no progression. Recruiting --> Completed
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 28, 2012
P2, N=60, Completed, Sponsor: Hamilton Health Sciences Corporation
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion, Adherence: CONVOY: Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI) (clinicaltrials.gov) - May 27, 2012
P=N/A, N=102, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Completed
- Epratucyn (epratuzumab) / Gilead
Enrollment change: Study of Epratuzumab in Systemic Lupus Erythematosus (clinicaltrials.gov) - May 24, 2012
P3, N=0, Withdrawn, Sponsor: UCB, Inc.
Recruiting --> Completed N=408 --> 0
- |||||||||| Plivensia (sirukumab) / J&J
New P3 trial: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) (clinicaltrials.gov) - May 24, 2012
P3, N=840, Recruiting, Sponsor: Janssen Research & Development, LLC
- Trial initiation date: A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus (clinicaltrials.gov) - May 23, 2012
P1, N=40, Recruiting, Sponsor: Brigham and Women's Hospital
N=408 --> 0 Initiation date: Dec 2011 --> May 2012
- Enrollment change: Safety and Efficacy Study of NovoRapid (clinicaltrials.gov) - May 23, 2012
P=N/A, N=0, Withdrawn, Sponsor: Novo Nordisk
Initiation date: Dec 2011 --> May 2012 N=2500 --> 0
- |||||||||| Sativex (nabiximols) / Jazz
New P3 trial: A Study of the Long-term Safety of Sativex Use (clinicaltrials.gov) - May 23, 2012
P3, N=507, Completed, Sponsor: GW Pharmaceuticals Ltd.
- ||| Trial completion: A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use (clinicaltrials.gov) - May 23, 2012
P=N/A, N=90, Completed, Sponsor: Medtronic Diabetes
N=2500 --> 0 Recruiting --> Completed
- | prednisolone / Generic mfg.
Trial initiation date: TryCort: Diagnostic Value of Oral Prednisolone Test for Rheumatoid Arthritis (clinicaltrials.gov) - May 22, 2012
P2/3, N=130, Enrolling by invitation, Sponsor: Rheumazentrum Ruhrgebiet
Recruiting --> Completed Initiation date: Oct 2011 --> Feb 2012
- | prednisolone / Generic mfg.
Enrollment open: TryCort: Diagnostic Value of Oral Prednisolone Test for Rheumatoid Arthritis (clinicaltrials.gov) - May 22, 2012
P2/3, N=130, Enrolling by invitation, Sponsor: Rheumazentrum Ruhrgebiet
Initiation date: Oct 2011 --> Feb 2012 Not yet recruiting --> Enrolling by invitation
- ||| ceralifimod (ONO 4641) / Ono Pharma
Enrollment closed: DreaMS: Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - May 22, 2012
P2, N=343, Active, not recruiting, Sponsor: EMD Serono
Not yet recruiting --> Enrolling by invitation Enrolling by invitation --> Active, not recruiting
- |||||||||| Plivensia (sirukumab) / J&J
New P3 trial: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) (clinicaltrials.gov) - May 21, 2012
P3, N=1650, Recruiting, Sponsor: Janssen Research & Development, LLC
- | famotidine/ibuprofen / Generic mfg.
Enrollment open: Open-label Safety and Pharmacokinetic Study of DUEXIS (clinicaltrials.gov) - May 21, 2012
P4, N=30, Recruiting, Sponsor: Horizon Pharma, Inc.
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment change: RoBIK-1: Brain Computer Interface for Communication in ICU: a Feasibility Study (clinicaltrials.gov) - May 20, 2012
P=N/A, N=12, Completed, Sponsor: University of Versailles
Not yet recruiting --> Recruiting N=10 --> 12
- Trial completion: RoBIK-1: Brain Computer Interface for Communication in ICU: a Feasibility Study (clinicaltrials.gov) - May 20, 2012
P=N/A, N=12, Completed, Sponsor: University of Versailles
N=10 --> 12 Recruiting --> Completed
- Trial completion: Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis (clinicaltrials.gov) - May 20, 2012
P=N/A, N=362, Completed, Sponsor: Zhi-Hong Liu, M.D.
Recruiting --> Completed Recruiting --> Completed
- Actemra IV (tocilizumab) / Roche, JW Pharma
New P1/2 trial: Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis (clinicaltrials.gov) - May 20, 2012
P1/2, N=5, Recruiting, Sponsor: Eric B. Suhler
- Lisofylline / Islet Sci
New P1/2 trial: Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - May 20, 2012
P1/2, N=1, Terminated, Sponsor: Eastern Virginia Medical School
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Compliance: An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - May 20, 2012
P=N/A, N=197, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Completed
- Trial completion: The Effects of Attention Retraining in MS (clinicaltrials.gov) - May 17, 2012
P=N/A, N=97, Completed, Sponsor: Finnish MS Society
Recruiting --> Completed Active, not recruiting --> Completed
- | Doptelet (avatrombopag) / SOBI
Trial completion: Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. (clinicaltrials.gov) - May 17, 2012
P1, N=36, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- | leucovorin calcium / Generic mfg.
New P2 trial: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - May 16, 2012
P2, N=144, Recruiting, Sponsor: University of Arkansas
- ||| Promacta (eltrombopag) / Novartis
Enrollment closed: A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 16, 2012
P4, N=150, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Active, not recruiting
- leflunomide / Generic mfg.
Clinical: A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications (clinicaltrials.gov) - May 15, 2012
P=N/A, N=1748, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
- hydroxychloroquine / Generic mfg.
New P3 trial: Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome (clinicaltrials.gov) - May 15, 2012
P3, N=39, Completed, Sponsor: Seoul National University Hospital
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P3 trial: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - May 15, 2012
P3, N=185, Active, not recruiting, Sponsor: Allergan
- | Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
New P1 trial: A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - May 15, 2012
P1, N=20, Completed, Sponsor: Eli Lilly and Company
- | New P4 trial: Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections (clinicaltrials.gov) - May 14, 2012
P4, N=100, Recruiting, Sponsor: Yonsei University
- |||||||||| Sativex (nabiximols) / Jazz
New P3 trial: A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis (clinicaltrials.gov) - May 13, 2012
P3, N=337, Completed, Sponsor: GW Pharmaceuticals Ltd.
- ||||| blisibimod (A-623) / Anthera Pharma
New P2 trial: BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (clinicaltrials.gov) - May 13, 2012
P2, N=100, Not yet recruiting, Sponsor: Anthera Pharmaceuticals